Cell Therapy for Melanoma

Cell therapy represents one of the most ambitious frontiers in melanoma treatment—where a patient’s own immune system is not just supported, but radically expanded, engineered, and redeployed. In this lecture, Dr. Rodabe N. Amaria, M.D. explores the current landscape of cell-based therapies for advanced melanoma, focusing on their role as powerful—yet intensive—options for patients whose disease has progressed despite standard immunotherapy. The story begins with Tumor-Infiltrating Lymphocytes (TILs), a concept rooted in discoveries from the late 20th century, when researchers first demonstrated that immune cells extracted from tumors could be expanded and reinfused to fight cancer. Decades later, this approach has evolved into therapies like Lifileucel, now studied in patients with PD-1–refractory melanoma. While response rates are meaningful, the treatment comes with significant toxicity due to the need for chemotherapy conditioning and high-dose cytokines. From this foundation, newer approaches are emerging. Engineered TILs such as OBX-115 aim to reduce toxicity by enabling the cells to produce their own supportive signals. Meanwhile, T-cell receptor (TCR) therapies like IMC-203 take a more targeted approach, genetically programming immune cells to recognize specific tumor antigens. These innovations reflect a broader effort to preserve the potency of cell therapy while making it safer and more precise. At the heart of this field lies a difficult balance: how to identify which patients will truly benefit from such intensive treatments, and how to deliver them with fewer risks. This video offers a clear, research-driven view into that challenge—and the possibilities ahead.